Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: A nationwide Taiwan database analysis of long‐term outcome predictors

Shi, Hon-Yi; Wang, Shen‐Nien; Wang, Shih Chin; Chuang, Shih‐Chang; Chen, Chun-Min; Lee, King‐Teh

doi:10.1002/jso.23521

“…Better long-term survival may be achieved by patients undergoing resection after downstaging [48]. For resectable liver cancer, preoperative TACE is not associated with improved survival [59, 60] (evidence level 2).…”

Section: Treatmentmentioning

confidence: 99%

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

Zhou¹,

Sun²,

Wang³

et al. 2018

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) (about 85–90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. Summary: This guideline presents official recommendations of the National Health and Family Planning Commission of the People’s Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologists) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations. Key Messages: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.

show abstract

“…However, there is no evidence that TACE followed by resection increases disease-free survival compared with resection only in resectable HCC. 429 …”

Section: Adjuvant Therapymentioning

confidence: 99%

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Korea

¹

2015

View full text Add to dashboard Cite

The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.

show abstract

“…Even for resectable HCC, TACE can be applied prior to resection as a neoadjuvant therapy. However, there is no evidence that TACE followed by resection increases disease-free survival compared with resection only in resectable HCC ( 429 ).…”

Section: Adjuvant Therapymentioning

confidence: 99%

2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Park¹,

Lee²,

Suh³

et al. 2015

View full text Add to dashboard Cite

The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.

show abstract

Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: A nationwide Taiwan database analysis of long‐term outcome predictors

Cited by 31 publications

References 39 publications

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About